Christopher D. Alafi, Director at Intra-Cellular Therapies, Inc. (ITCI), bought 49,500 shares at $29.60 ($1.5M) on 2020-09-14, disclosed to the SEC on 2020-09-14.
Open-market purchase of $1.5M ITCI by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| ITCI | BUY | 2020-09-11 | $590K | — | Filing → |
| ITCI | BUY | 2019-09-11 | $9.8M | — | Filing → |
| ITCI | BUY | 2019-09-04 | $1.1M | — | Filing → |